There is no safe therapeutic window of time for using NSAIDs in patients with prior myocardial infarction. Even short-term treatment with most NSAIDs appears associated with increased risk of death and recurrent MI. In general, NSAIDs should be limited from a cardiovascular safety point of view, according to a study published in Circulation.
There is no safe therapeutic window of time for using nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with prior myocardial infaction (MI). Even short-term treatment with most NSAIDs appears associated with increased risk of death and recurrent MI. In general, NSAIDs should be limited from a cardiovascular safety point of view, according to a study published in Circulation.
To analyze the risk of death and recurrent MI according to duration of NSAID treatment, investigators identified a population of patients in the Danish National Patient Registry with first-time admission for MI (ICD-10, I21 through I22) from January 1, 1997, to December 31, 2006, and no prior admission for MI in the previous 19 years.
Of the 83,677 patients included, 42.3% received NSAIDs during follow-up. The most commonly used NSAIDs were ibuprofen (23.2%) and diclofenac (13.4%); the most commonly used selective cyclooxygenase-2 (COX-2) inhibitors were rofecoxib (4.7%) and celecoxib (4.8%). Overall NSAID treatment was significantly associated with an increased risk of death/recurrent MI at the beginning of the treatment, and the risk persisted throughout the course of treatment.
Diclofenac was associated with the highest risk (HR, 3.26; 95% CI, 2.57 to 3.86 for death/MI at day 1 to 7 of treatment), and the risk persisted throughout the course of treatment. Ibuprofen was associated with an increased risk when used for more than 1 week; however the risk was lower than the risk with the COX-2 selective inhibitors and diclofenac. Rofecoxib was associated with increased risk of death after a treatment range of 7 to 14 days, and celecoxib was associated with increased risk of death after a treatment range of 14 to 30 days. Naproxen was not associated with an increased risk of death or MI for the entire treatment duration.
“These results challenge the view that NSAIDs are not harmful during short-term (1 week) treatment and indicate that a revision of current recommendations regarding NSAID treatment in patients with established cardiovascular disease is required,” the authors wrote.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More